• Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Log in to your Inderes Free account to see all free content on this page.
Create account

Spermosens

0.01 SEK

0.00 %

Less than 1K followers

SPERM

Spotlight Stock Market

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
0.00 %
+10.64 %
+18.18 %
+79.31 %
+79.31 %
+30.00 %
-92.64 %
-99.27 %
-98.93 %

Spermosens operates in the medical technology sector. The company specializes in the development of medical technology products. The product portfolio is broad and includes products for male infertility and individually tailored fertility treatments. Research and development is conducted via its own technological platform that analyzes sperm quality, which is further used for medical support and potential fertilization. The largest operations are found in the Nordic market.

Read more
Market cap
33M SEK
Turnover
259.36 SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
EPS and dividend
Financial calendar
20.8.
2026

Interim report Q2'26

12.11.
2026

Interim report Q3'26

11.2.
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release18.06.2026 klo 13.59

Bulletin from Annual General Meeting in Spermosens AB (publ)

Spermosens
Regulatory press release28.05.2026 klo 16.45

Spermosens publishes annual report for the financial year 2025

Spermosens
Regulatory press release28.05.2026 klo 16.39

Spermosens publicerar årsredovisning för räkenskapsåret 2025

Spermosens

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Regulatory press release18.05.2026 klo 10.14

Spermosens: NOTICE OF ANNUAL GENERAL MEETING 2026 IN SPERMOSENS AB (publ)

Spermosens
Regulatory press release18.05.2026 klo 10.11

Spermosens: KALLELSE TILL ÅRSSTÄMMA 2026 I SPERMOSENS AB (publ)

Spermosens
Press release11.05.2026 klo 16.59

Spermosens AB (publ) to Host Live Q&A Webcast on 19 May 2026

Spermosens
Regulatory press release07.05.2026 klo 19.08

Spermosens secures SEK 4.85 million capital facility to support development and commercialization

Spermosens
Regulatory press release07.05.2026 klo 09.37

Spermosens AB (publ) INTERIM REPORT JANUARY - MARCH 2026

Spermosens
Press release29.04.2026 klo 15.30

Spermosens reports JUNO-Checked Generation 3 clinical validation study on track

Spermosens
Regulatory press release08.04.2026 klo 15.32

Spermosens completes development of JUNO-Checked Generation 3 and initiates clinical validation study

Spermosens
Press release25.03.2026 klo 12.55

Spermosens AB (publ) Issues Final Reminder for Tomorrow's Live Q&A Webcast

Spermosens
Press release16.03.2026 klo 17.13

Spermosens AB (publ) to Host Live Q&A Webcast Following Recent Progress

Spermosens
Regulatory press release11.02.2026 klo 10.58

Spermosens AB (publ)YEAR-END REPORT JANUARY - DECEMBER 2025 - CORRECTED

Spermosens
Regulatory press release11.02.2026 klo 10.05

Spermosens AB (publ)YEAR-END REPORT JANUARY - DECEMBER 2025

Spermosens
Regulatory press release26.01.2026 klo 14.40

Spermosens and RSI sign Memorandum of Understanding to advance male fertility diagnostics in the US

Spermosens
Regulatory press release16.01.2026 klo 11.22

Spermosens and Sapyen sign Memorandum of Understanding to advance male fertility diagnostics

Spermosens
Regulatory press release09.12.2025 klo 09.45

Spermosens shares progress and plans for partner-driven commercialization

Spermosens
Regulatory press release08.12.2025 klo 14.41

Spermosens announces outcome of exercise of warrants series TO 4

Spermosens
Regulatory press release24.11.2025 klo 18.12

Spermosens announces last day of trading for warrants of series TO 4

Spermosens
Regulatory press release18.11.2025 klo 11.21

Spermosens receives patent approval in China

Spermosens